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PHARMACOLOGY
NEW ANTIRETROVIRAL DRUGS: WHAT’S ON
THE HORIZON IN 2005?
Despite the present number of available antiretrovirals (ARVs), there continues to be a need for new medications with improved
tolerability, and activity against resistant virus. This article will review three groups of ARVs: those available in North America and
Europe but not yet registered in South Africa; new formulations of drugs for which the parent formulations are already available
in South Africa; and promising new compounds in early clinical stages of development. Table I shows the year of approval of
ARVs available for treatment of HIV-infected individuals, in both the USA and South Africa and Table II summarises the
characteristics and rationale for new ARVs. 
There are 7 compounds within this class available for therapy;
however, cross-resistance, mitochondrial toxicity, overlapping
side-effect profiles and the use of dual NRTIs as a backbone of
many triple therapy regimens all combine to limit NRTI-
therapeutic options. Members of this class under development
include both new molecules and new formulations of existing
approved drugs.
Tenofovir disoproxil fumarate is a diester pro-drug of the
nucleotide analogue of adenosine 5´-monophosphate. It was
registered in the USA in October 2001, initially for patients
failing previous therapies and recently extended to use in first-
line therapy.1,2 It also has activity against hepatitis B virus.
Bioavailability is improved when administered with food (40%),
and it is generally well tolerated. The prolonged elimination
half-life allows once-daily administration, with the major route
of elimination being both renal glomerular filtration and active
tubular secretion. The recommended dosage is one 300 mg
tablet daily, if creatinine clearance > 50 ml/min. Co-
administration with didanosine results in significantly raised
didanosine levels. It is therefore recommended that the dose of
co-administered didanosine be reduced from 400 mg to 250
mg per day.  New data suggest that this combination should be
used with caution, as it is associated with increased early
virological failures and CD4 declines even in those achieving
viral suppression. It has been postulated that the combination
of these adenosine derivatives may be antagonistic in vivo. Co-
administration with the protease inhibitors (PIs), atazanavir,
indinavir and lopinavir also results in increased tenofovir levels
and should prompt increased surveillance for renal toxicity.
Atazanavir levels are decreased by tenofovir and ritonavir
boosting should be used when co-administered. However, when
combined with 3TC (lamivudine) or FTC (emtricitabine),
tenofovir has shown antiretroviral efficacy in both
NEW NUCLEOSIDE REVERSE TRANSCRIPTASE
INHIBITORS (NRTIs)
Year of registration 
USA RSA
Nucleoside reverse transcriptase 
inhibitors 
Zidovudine  (AZT/ZDV) 1987 1989
Didanosine (ddI) 1991 1992
Zalcitabine (ddC) 1992 1994
Stavudine (D4T) 1994 1998
Lamivudine (3TC) 1995 1996
Abacavir (ABC) 1998 2001
Enteric-coated ddI 2000 N/R
Emtricitabine (FTC) 2003 N/R
Nucleoside reverse transcriptase 
inhibitor     
Tenofovir (TFV) 2001 N/R
Non-nucleoside reverse 
transcriptase inhibitors 
Nevirapine (NVP) 1996 1998
Delaviradine (DLV) 1997 N/R
Efavirenz (EFV) 1998 1999
Protease inhibitors 
Saquinavir (SQV) 1995 1997
Ritonavir (RTV) 1996 1997
Indinavir (IND) 1996 1996
Nelfinavir (NLF) 1997 1999
Amprenavir (AMP) 1999 2001
Lopinavir/ritonavir (LPV/r) 2000 2001
Atazanavir (ATZ) 2003 N/R
Fosamprenavir 2003 N/R
Entry inhibitor  
Enfuvirtide (T-20) 2003 N/R
N/R = not registered as of December 2004. 
TABLE I. ANTIRETROVIRAL DRUGS REGISTERED
IN THE USA AND SOUTH AFRICA, 2004
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antiretroviral-experienced and naïve patients. Resistance is
associated with the K65R mutation, which occurs infrequently
in patients receiving tenofovir. Adverse events associated with
tenofovir use include asthenia, headache and gastrointestinal
upset. Tenofovir has the least propensity for mitochondrial
toxicity of all the currently approved NRTIs. Nephrotoxicity,
particularly tubular dysfunction, is less common than reported
with use of the earlier nucleotide compound adefovir.  
FTC is a fluorinated cytidine analogue approved by the Food and
Drug Administration (FDA) in July 2004 for use in combination
therapy of adult HIV infection.1,2 It is closely related to 3TC but
has a longer elimination half-life, allowing once-daily
administration. Potency and resistance profile are similar to
3TC, although it appears that the M184V mutation emerges
more slowly under FTC than 3TC selective pressure. The dose of
FTC is a single 200 mg capsule once a day.
Racivir is a mixture of FTC and its positive enantiomer with
potent anti-HIV and anti-HBV activity. It is well tolerated and
dosed once daily. In a phase I/II dosing study of 200, 400 and
600 mg o.d. in treatment-naïve volunteers, there was a rapid
decline in viral load, which remained suppressed for 14 days
after cessation of therapy.3
SPD 754 is a deoxycytidine analogue that has in vitro activity
against HIV strains with the 3TC resistance-associated M184V
mutation. SPD 754, however, has reduced activity against
mutations associated with broad resistance to NRTIs (69
insertions and Q151M). The molecule is the negative
enantiomer of dOTC, a mixture of both positive and negative
enantiomers. The development of dOTC was discontinued
because of toxicity observed in primates, which was attributed
to the positive enantiomer. A 10-day phase I study of SPD 754
in treatment-naïve patients receiving one of 5 dosages showed
dose-dependent antiviral activity with no development of new
RT mutations.4 SPD 754 had the least mitochondrial toxicity in
a tissue culture assay when compared with 9 other NRTIs
including 3TC.
D-D4FC is another deoxycytidine analogue with in vitro activity
against NRTI-resistant HIV strains. When dosed at 200 mg once
daily for 10 days in vivo activity was demonstrated in both
treatment-naïve and treatment-experienced patients
harbouring HIV mutations associated with high-level resistance
to other NRTIs.5
Amdoxovir (DAPD) is a guanine analogue, with a potentially
attractive resistance profile. In vitro activity has been
demonstrated against HIV strains resistant to AZT and 3TC, ddI,
ddC and ABC and strains with the multiple NRTI-resistant SS
insertions at codons 68 and 69. Virus containing L74V and the
double mutations K65R and Q151M are fully resistant to DAPD.
Excretion is predominantly renal and because of its low
Drug name Type of drug Rationale for development Development phase  
Tenofovir Adenosine analogue nucleotide RTI Once daily with unique NRTI resistance FDA approved, Oct 2001
profile
FTC Cytidine analogue NRTI Once daily cytidine analogue FDA approved, July 2004
Racivir Mixture of FTC with positive enantiomer, Potent anti-HIV effect Phase II
NRTI
SPD 754 Deoxycytidine analogue NRTI Cytidine analogue with activity against Phase III
M184V mutation
D-D4FC Deoxycytidine analogue NRTI Activity against NRTI resistance strains Phase II
Amdoxovir Guanine analogue NRTI Activity against NRTI resistance strains Phase II
ddI-EC Enteric-coated reformulation of Obviates antacid buffering, less GI FDA approved, Oct 2000
didanosine, NRTI adverse events and drug-drug 
interactions
Stavudine ER Extended-release formulation of Once-daily dosing FDA approved, Dec 2002
stavudine, NRTI
Capravirine Imidazole analogue NNRTI Extended resistance profile, 2 or 3 pol Phase III
mutations required 
TMC-125 Diaminopyrimidine NNRTI Active against highly NNRTI resistant virus Phase IIA
Atazanavir Azopeptide PI Once-daily PI with ‘lipid-friendly’ profile FDA approved, June 2003
A-681799 Azopeptide PI Extended PI resistance profile Phase II
Fosamprenavir Calcium phosphate ester of Pro-drug of amprenavir with lower FDA approved, Oct 2003
amprenavir, PI pill burden
Tipranavir Nonpeptidic PI Extended PI resistance profile Phase III
TMC-114 Nonpeptidic PI with bis-THF &  Extended PI resistance profile Phase II
sulfonamide isotere
T-20 36 amino acid peptide fusion inhibitor Peptide binding to viral gp41, blocking FDA approved, March 2003
membrane fusion
TABLE II. SUMMARY OF NEW ANTIRETROVIRAL DRUGS WITH RATIONALE FOR DEVELOPMENT
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solubility it can precipitate in the urine. There may be a risk of
obstructive nephropathy in patients with renal impairment.
Study DAPD-150 is an open-label study of 300 mg and 500 mg
DAPD twice daily, in heavily pretreated (median 7.7 years)
individuals with a median of 3 NRTI-resistant mutations at
baseline. At a 12-week interim analysis the addition of DAPD to
optimised therapy achieved a 0.5 log decline in viral load in
58% of subjects, and a 1.0 log decline in 42%. There was a high
rate of discontinuation from this study, however, including 5 of
18 patients developing non-sight-threatening lens opacities.6
DAPD in vitro activity was enhanced 10-fold by combination
with ribavirin, an inosine monophosphate dehydrogenase
inhibitor.7
Videx EC is an enteric-coated formulation of ddI, which was
approved for ARV use by the FDA in October 2001. Videx EC is
taken once daily on an empty stomach, but the absence of
antacid allows other medications to be taken at the same time.
The removal of the calcium- and magnesium-based pH buffers
results in fewer gastrointestinal side-effects. Videx EC is now
the predominant formulation of ddI used in North America and
Europe.
Extended-release stavudine (d4T XR) was approved for ARV use
by the FDA in December 2002, and can be taken once a day.  A
randomised double-blind placebo-controlled trial compared
d4T XR with the standard twice-daily immediate-release (IR)
capsules and showed similar antiviral and immunological
profiles in both arms. Discontinuations due to adverse events
were similar in both.
Currently available NNRTIs cannot be used sequentially
following initial NNRTI failure because resistance to any one
individual drug usually results in high-level resistance to all
members of the NNRTI class. There is therefore considerable
interest in second-generation NNRTIs, which have
demonstrated in vitro activity against HIV strains with
resistance to nevirapine and efavirenz. Reverse transcriptase
mutations such as K103N and Y181C, conferring resistance
against NNRTIs, result in substitution of large amino acids
around the NNRTI-binding pocket, thereby decreasing RT-
NNRTI contact. Second-generation NNRTIs molecules retain the
ability to attach to the RT-NNRTI binding pocket even when the
conformational three-dimensional structure is altered by the
presence of these amino acids. 
Capravirine is a second-generation NNRTI, which requires 2 or
3 key mutations to develop high-level resistance, in contrast to
currently approved NNRTIs that have high-level resistance
associated with a single mutation of the pol gene. In patients
who had previously failed NNRTI therapy, capravirine 1 400 mg
b.d. in combination with nelfinavir and 2 NRTIs was superior to
either 2 100 mg of capravirine or placebo with nelfinavir and 2
NRTIs, but results did not reach statistical significance.8 Clinical
trials were suspended following the discovery that the drug
caused vasculitis in dogs; development was resumed following
safety assessment.
TMC-125 is a diaminopyrimidine NNRTI with potent in vitro
activity against HIV, including clinical isolates with high-level
resistance to current NNRTIs including K103N and Y181C
mutations. A 1-week monotherapy study of 900 mg twice daily,
in treatment-naïve subjects, produced a 2 log decline in viral
load. In NNRTI-experienced patients, substitution of the
existing NNRTI of the treatment regimen with TMC-125
resulted in a 1.0 log decline in viral load at 7 days.9
Limited sequential use of PIs is possible because of the initially
different resistance pathways associated with use of individual
members of this class. However, acquisition of increasing
numbers of PI mutations results in wider cross-resistance.
There is therefore an ongoing need for new PIs with distinct
resistance profiles and activity against highly PI-resistant HIV
strains. PIs are also associated with derangements of lipid and
glucose metabolism and associated changes in body
morphology, which has motivated the search for more
‘metabolic-friendly’ PIs.
Atazanavir, approved in July 2003 for use in the USA, is an
azopeptide PI with freedom from the cholesterol and
triglyceride abnormalities that are associated with other
members of the PI class. Oral bioavailability is variable but is
improved when taken with food. There is a low pill burden and
the recommended dosage is 400 mg (2 tablets) taken once daily.
An I50L substitution appears to be a unique signature mutation
of this PI, which is associated with increased in vitro
susceptibility to other PIs.10 Atazanavir is extensively hepatically
metabolised and largely excreted in faeces. An increase in
unconjugated bilirubin can occur which is related to serum
drug level and patients’ glucoronidation enzyme genotype
(Gilbert’s trait). Elimination half-life is 7 hours and
bioavailability is increased by 70% with light meals. Atazanavir
blood levels are boosted by co-administration with ritonavir, a
CYP3A4 hepatic enzyme inhibitor, but the role of this
combination in salvage therapy continues to be delineated.
Important ARV interactions requiring ritonavir boosting of
atazanavir include the NNRTIs, efavirenz and nevirapine
CYP3A4 inducers, and the NRTI tenofovir. Dual PI combination
of atazanavir and saquinavir (600/1200 mg q.d.) in combination
with 2 NRTIs has been explored but was not inferior to ritonavir
and saquinavir (400/400 mg q.d.). Once-daily dosing and a
benign metabolic profile make this an attractive first-line PI,
particularly in those with increased cardiovascular risk factors.
A-681799 is structurally related to atazanavir with in vitro
activity against lopinavir-resistant virus.11 Pharmacokinetic
studies indicate that ritonavir boosting is necessary.
Fosamprenavir is a calcium phosphate ester pro-drug of
amprenavir, approved for ARV use in the USA in October 2003.
It is almost completely hydrolysed to amprenavir and
NEW NON-NUCLEOSIDE REVERSE TRANSCRIPTASE
INHIBITORS (NNRTIs)
NEW PROTEASE INHIBITORS
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phosphate by cellular phosphatases in the gut epithelium. It is
formulated in 476 mg tablets with a side-effect profile that is
similar to the parent drug. The adult dosage of 3 - 4 tablets
twice daily results in a considerably decreased pill burden
compared with amprenavir (16 tablets). Once-a-day dosing is
possible if fosamprenavir is combined with ritonavir.12
Unboosted fosamprenavir is associated with moderate
elevations of total cholesterol but an increased HDL
component.  
Tipranavir is a non-peptidic HIV PI, with interest in the
compound driven by in vitro data indicating that it has activity
against strains of HIV that are multiply resistant to other
current PIs. The dosing and formulation have been problematic
and therapeutic boosting with ritonavir is necessary. The BI
1182.52 study of 3 doses of tipranavir/ritonavir (500/100 mg,
500/200 mg and 750/200 mg) in 216 heavily pretreated
patients, with at least one PI resistance-associated mutation at
baseline (not > 1 of 82L/T, 84V or 90M), achieved target plasma
concentrations of tipranavir in 77% of the medium- and high-
dose groups. A 1.0 log reduction in viral load was seen in those
receiving the 2 higher dosages; however, the medium dose
(500/100 mg) was safer and better tolerated.13 The presence of
> 2 PI resistance-associated mutations at baseline resulted in
loss of tipranavir efficacy. Currently the 500/100 mg dosage has
been selected for phase III development. Resist 1, an ongoing
study of 620 heavily pretreated patients (median 12 ARVs),
demonstrated that tipranavir had significant activity against
highly resistant virus but outcomes were improved when used
with another novel agent such as T-20. 
TMC-114 has potent in vitro and in vivo activity against PI-
resistant strains. The compound is mainly metabolised by the
CYP3A4 hepatic enzyme system and is co-administered with
ritonavir. A phase I/II study of 3 regimens of TMC-114 with
ritonavir (300/100 mg b.i.d., 600/100 mg b.i.d. and 900/100 mg
q.d.) substituted for a currently failing PI in heavily pretreated
patients showed between 1.2 and 1.5 log decrease in viral load
at 14 days.14 The most commonly reported adverse events were
mild to moderate gastrointestinal and CNS-related effects.
HIV infection of uninfected human cells is an active process
requiring complex interactions between both viral and human
cellular receptors, necessary before fusion of viral and cellular
membranes. There are at least three components of this
process: viral-cell attachment; chemokine co-receptor
attachment; and gp41 conformational change resulting in
fusion of viral and target cell membranes. There is considerable
clinical experience with the fusion inhibitor (T-20), which was
registered for use in USA and Europe in 2003. T-20 or
enfuvirtide is a 36 amino acid peptide, which inhibits HIV fusion
with T-cells and thereby inhibits cellular infection.15 The
molecule acts extracellularly at nanomolar concentrations.
Membrane fusion results from the interaction between two
heptad repeat regions (HR1 and HR2) of gp41, which triggers a
contraction of gp41 drawing the two membranes together. T-20
protein binds to HRI, thereby blocking its interaction with HR2.
Mutations in the HR1 region of gp41 can result in resistance to
T-20; however, there is no evidence of cross-resistance to other
ARVs including the newer fusion inhibitors under development.
The usual dosage of T-20 is 90 mg (1 ml) administered by
subcutaneous injection twice daily, and it should be augmented
with other potent drugs. The formulation is a lyophilised
powder, which is dissolved in sterile water before use. The
reconstituted solution should be refrigerated and used within
24 hours. Irritation at the injection site is the commonest
adverse event and hypersensitivity reactions are rare. An
increase in bacterial pneumonia was observed in trial patients
receiving T-20 compared with those receiving placebo, but the
cause is uncertain. T-20 has a role in salvage therapy of heavily
pretreated individuals, but its manufacture is complex,
requiring multiple steps, and it is likely to remain a costly drug. 
ARV therapy remains a rapidly evolving field allowing
prolonged survival of our patients. Chronic management not
only requires potent antiviral effect but also less demanding
and less toxic regimens. The number of new compounds in the
production pipeline and the increase in drug targets will
increase our ability to fight this highly mutable virus.
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Medical Doctors
The award winning PHRU, a large research unit dedicated to finding
ways to mitigate the impact of the HIV epidemic, has vacancies for
Doctors, including Specialists with an interest in Paediatrics and
Adults. The incumbents must be willing to learn and be part of a highly
motivated team. There is opportunity for exposure to clinical research
methods including GCP, computer literacy and HIV treatment and
care. The Unit is located at Chris Hani Baragwanath Hospital where it
has a primary care clinic. The positions may include travel to clinics in
Soweto. Other attractions include good working hours, mentoring and
support for your own research, and an excellent working environment.
These positions would suit people who either want to embark on a
career in clinical research, or are established researchers.
Experience and skills required: • Registered as a Medical
Practitioner with the Health Professions Council of South Africa
• Experience in HIV treatment in paediatric and adults • An interest in
working with HIV-infected/affected children and adults • Ability to
communicate in local languages would be an advantage • Computer
literacy or a willingness to become computer literate • Meticulous
attention to detail following study protocols and recording symptoms
and clinical signs • Good writing and verbal communication skills.
Duties will include: • Participating in all phases of the research
process • Assisting in conducting HIV research studies in accordance
with ICH GCP and the specifics of the protocol • Providing clinical
support for research studies • Providing comprehensive medical care
to patients enrolled in studies • Taking histories and examining
patients on their follow up visits • Ensuring timely recruitment for all
research studies and protocols • Working together with the study
team in order to optimise research strategies • Be accountable for
study planning and logistics • Being part of the research team making
recommendations on how to make studies run efficiently, suggestions
for future research and being involved in report findings.
The positions are offered on a 1-year contract basis with the possibility
of extension, subject to funding availability and individual performance. 
Please send an application letter with an updated CV,
including the names and contact information of at least 2
professional references, to Nthabiseng Thabethe by fax
on 011 989-9798 or e-mail to nthabethe@witshealth.co.za
Initial closing date: 30 April 2005, BUT we will accept
applications on an ongoing basis until end of Nov 2005.
SECOND NATIONAL AIDS CONFERENCE 
The second South African AIDS Conference will be held in Durban in June 2005. 
The theme of this year’s conference is Unity and Accountability, reflecting the feeling of opti-
mism and hope and the many new challenges brought about by the antiretroviral treatment
programme.
The formal conference programme will be structured around four tracks: Basic and Clinical
Sciences; Epidemiology, Prevention and Public Health; Social and Economic Sciences,
Human Rights and Ethics; and Best Practices. 
The 2nd South African AIDS Conference will be held at the International
Convention Centre in Durban on 7 - 10 June 2005. More information may
be obtained from www.sa-aidsconference.com
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